KR920700041A - 치료화합물과 그의 조성 및 용도 - Google Patents

치료화합물과 그의 조성 및 용도

Info

Publication number
KR920700041A
KR920700041A KR1019900702562A KR900702562A KR920700041A KR 920700041 A KR920700041 A KR 920700041A KR 1019900702562 A KR1019900702562 A KR 1019900702562A KR 900702562 A KR900702562 A KR 900702562A KR 920700041 A KR920700041 A KR 920700041A
Authority
KR
South Korea
Prior art keywords
vasodilator
calcium antagonist
blood supply
deficiency
cerebral
Prior art date
Application number
KR1019900702562A
Other languages
English (en)
Inventor
메리 니이 우슬라
베네트 테렌스
마가레트 가아디너 셀리아
Original Assignee
원본미기재
셀텍크 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 셀텍크 리미티드 filed Critical 원본미기재
Publication of KR920700041A publication Critical patent/KR920700041A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

치료화합물과 그의 조성 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 대뇌혈관 혈액 공급결핍의 치료에 있어서, 병용투약용 혈관확장제와 칼슘 길항제.
  2. 대뇌 혈관 혈액공급결핍의 치료에서 병용투약용 칼시토닌 유전자 관련 펩타이드와 니모디핀.
  3. 효과적인 양의 칼슘 길항제와 혈관 확장제를 환자에게 투여함을 포함하는 대뇌혈관 혈액공급결핍의 인간 환자에 대한 치료방법.
  4. 혈관 확장제와 칼슘 길항제를 포함하는 약학적 조성물.
  5. 약학적으로 허용 가능한 담체, 부형제나 희석제와 함께 단일제형내에, 병용투약시 혈압에 크게 영향을 미치지 않거나, 심박도수의 현저한 증가를 일으키지 않고 대뇌혈관 혈액공급을 구별하여 증가시키는데 작용하는 양의 혈관 확장제와 칼슘 길항제를 각각의 단위 용량으로 포함하는 약학적 조성물.
  6. 제 5 항에 있어서, 약학적으로 허용 가능한 담체, 부형제나 혈관 확장제와 칼슘 길항제의 희석제와 조합시킴을 특징으로 하는 약학적 조성물의 제조방법.
  7. 대뇌혈관 혈액공급결핍 치료용 의약품의 제조를 위한 칼슘 길항제와 혈관 확장제의 병용 사용방법.
  8. 활성성분으로서 칼슘 길항제와 혈관 확장제를 병용함을 특징으로 하는 대뇌 혈액공급결핍의 치료용 약물.
  9. 칼슘 길항제와 혈관 확장제를 병용함을 특징으로 하는 대뇌혈액 공급 개선제.
  10. 환자에게 칼슘 길항제와 혈관 확장제를 병용함을 포함하는 대뇌 혈액 공급결핍의 치료방법.
    ※ 참고사항 : 최초 출원 내용에 의하여 공개하는 것임.
KR1019900702562A 1989-04-10 1990-04-10 치료화합물과 그의 조성 및 용도 KR920700041A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8908023.8 1989-04-10
GB898908023A GB8908023D0 (en) 1989-04-10 1989-04-10 Therapeutic compounds,compositions and uses thereof
PCT/GB1990/000540 WO1990011769A1 (en) 1989-04-10 1990-04-10 Therapeutic compounds, compositions and uses thereof

Publications (1)

Publication Number Publication Date
KR920700041A true KR920700041A (ko) 1992-02-19

Family

ID=10654739

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702562A KR920700041A (ko) 1989-04-10 1990-04-10 치료화합물과 그의 조성 및 용도

Country Status (7)

Country Link
EP (1) EP0433402A1 (ko)
JP (1) JPH03505462A (ko)
KR (1) KR920700041A (ko)
AU (1) AU5402490A (ko)
CA (1) CA2014282A1 (ko)
GB (1) GB8908023D0 (ko)
WO (1) WO1990011769A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤

Also Published As

Publication number Publication date
CA2014282A1 (en) 1990-10-10
JPH03505462A (ja) 1991-11-28
EP0433402A1 (en) 1991-06-26
GB8908023D0 (en) 1989-05-24
WO1990011769A1 (en) 1990-10-18
AU5402490A (en) 1990-11-05

Similar Documents

Publication Publication Date Title
YU48583B (sh) Postupak za pripremanje formulacije u obliku pilule za oralno davanje
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
IL135712A (en) Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis
EA199900499A1 (ru) Фармацевтическая композиция, включающая соединение, обладающее анти-xa активностью, и соединение антагонист агрегации тромбоцитов
NZ225242A (en) Pad printing process for manufacturing a pharmaceutical presentation and/or dosage form for active ingredients of drugs
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
WO1999040883A3 (en) Compositions and methods for the treatment of cystic fibrosis
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
KR880007073A (ko) 의 약 품
KR970025615A (ko) 암 전이 억제제
KR940013503A (ko) 동맥경화증의 예방 또는 치료용 약제학적 조성물
KR920702225A (ko) 약학 조성물
OA07029A (fr) Le chlorure de gallium, nouveau médicament anti-cancéreux.
KR930019224A (ko) 유산 위험 치료제
KR920700041A (ko) 치료화합물과 그의 조성 및 용도
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
KR830008678A (ko) 진통 조성물
KR910004190A (ko) 온단세트론의 신규 의학 용도
KR950701216A (ko) 레마세미드의 파킨슨병 치료 용도(use of remacemide for the treatment of parkinson's disease)
KR910004181A (ko) 생체내 유효성을 증가시키는 신규의 제약학적 경구 투여 형태
RU95110494A (ru) Средство с регулируемым высвобождением пентоксифиллина для лечения сосудистых заболеваний
KR910005856A (ko) 호흡기 질환 치료용 제약 조성물
ATE257377T1 (de) Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid